MedTrace Logo

A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777

NCT04931524 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-06-18

No results posted yet for this study

Summary

The purpose of this study is to assess the mass balance recovery and metabolic profiling and identification of 14C-ANG-3777 administered as a single IV dose.

Conditions

  • Healthy

Interventions

DRUG

carbon-14-[14C]-ANG-3777

Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • Sharan Sidhu, MBChB, BAO, MRCS, MFPM · Quotient Sciences - Nottingham, UK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2021-06-30
Completion
2021-06-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04931524 on ClinicalTrials.gov